Last reviewed · How we verify
HWK-016, MUCIN-16-targeted ADC — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HWK-016, MUCIN-16-targeted ADC (HWK-016, MUCIN-16-targeted ADC) — Whitehawk Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HWK-016, MUCIN-16-targeted ADC TARGET | HWK-016, MUCIN-16-targeted ADC | Whitehawk Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HWK-016, MUCIN-16-targeted ADC CI watch — RSS
- HWK-016, MUCIN-16-targeted ADC CI watch — Atom
- HWK-016, MUCIN-16-targeted ADC CI watch — JSON
- HWK-016, MUCIN-16-targeted ADC alone — RSS
Cite this brief
Drug Landscape (2026). HWK-016, MUCIN-16-targeted ADC — Competitive Intelligence Brief. https://druglandscape.com/ci/hwk-016-mucin-16-targeted-adc. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab